Demonstrate an understanding of the brain dysfunctions underlying the various symptoms/traits presenting in Borderline Personality Disorder (BPD) as well as the anatomy and physiology.
Demonstrate an understanding of the brain dysfunctions underlying the various symptoms/traits presenting in Borderline Personality Disorder (BPD) as well as the anatomy and physiology. Strongly Disagree
Demonstrate an understanding of the brain dysfunctions underlying the various symptoms/traits presenting in Borderline Personality Disorder (BPD) as well as the anatomy and physiology. Disagree
Demonstrate an understanding of the brain dysfunctions underlying the various symptoms/traits presenting in Borderline Personality Disorder (BPD) as well as the anatomy and physiology. Agree
Demonstrate an understanding of the brain dysfunctions underlying the various symptoms/traits presenting in Borderline Personality Disorder (BPD) as well as the anatomy and physiology. Strongly Agree
Identify the neuropharmacological interventions that have been shown to be effective in ameliorating the brain dysfunctions involved in BPD, and their modes of action.
Identify the neuropharmacological interventions that have been shown to be effective in ameliorating the brain dysfunctions involved in BPD, and their modes of action. Strongly Disagree
Identify the neuropharmacological interventions that have been shown to be effective in ameliorating the brain dysfunctions involved in BPD, and their modes of action. Disagree
Identify the neuropharmacological interventions that have been shown to be effective in ameliorating the brain dysfunctions involved in BPD, and their modes of action. Agree
Identify the neuropharmacological interventions that have been shown to be effective in ameliorating the brain dysfunctions involved in BPD, and their modes of action. Strongly Agree
Describe the target dose and blood level ranges of the anticonvulsant and dopaminergic agonist that have resulted in significant reductions in the symptoms/traits in BPD patients
Describe the target dose and blood level ranges of the anticonvulsant and dopaminergic agonist that have resulted in significant reductions in the symptoms/traits in BPD patients Strongly Disagree
Describe the target dose and blood level ranges of the anticonvulsant and dopaminergic agonist that have resulted in significant reductions in the symptoms/traits in BPD patients Disagree
Describe the target dose and blood level ranges of the anticonvulsant and dopaminergic agonist that have resulted in significant reductions in the symptoms/traits in BPD patients Agree
Describe the target dose and blood level ranges of the anticonvulsant and dopaminergic agonist that have resulted in significant reductions in the symptoms/traits in BPD patients Strongly Agree
Develop comfort in the described neuropharmacological protocol in their medical management of BPD patients through Q&A/discussion.
Develop comfort in the described neuropharmacological protocol in their medical management of BPD patients through Q&A/discussion. Strongly Disagree
Develop comfort in the described neuropharmacological protocol in their medical management of BPD patients through Q&A/discussion. Disagree
Develop comfort in the described neuropharmacological protocol in their medical management of BPD patients through Q&A/discussion. Agree
Develop comfort in the described neuropharmacological protocol in their medical management of BPD patients through Q&A/discussion. Strongly Agree